Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Fate Therapeutics Inc Logo

ARKK Holdings of Fate Therapeutics (FATE) - Updated Daily

Maxinomics.com icon
YouTube Logo
Date
Direction
Shares
Fund Weight
Fund
August 15, 2022
BUY161.0000.0001%ARKK
August 12, 2022
BUY3.478k0.0012%ARKK
August 11, 2022
BUY478.756k0.153%ARKK
August 8, 2022
SELL307.711k0.1033%ARKK
December 27, 2021
SELL13.150k0.0048%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$20.91
⚖️Weighting🧢Market Cap
1.95%$2.03b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
2129.44
🏋️‍♀️Weight Rank Across All Funds🌏Country
21🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$78.477.42%
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...